Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib plus Atezolizumab in Advanced Endocrine Neoplasms
NCT04400474Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Oct 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, atezolizumab in Neuroendocrine Neoplasm (NEN), anaplastic thyroid cancer (ATC), adrenocortical carcinoma (ACC), pheochromocytoma, Paraganglioma (PGL), sponsored by Spanish Group of Neuroendocrine Tumors. Started Oct 2020; status: completed.
02
Drugs
cabozantinibatezolizumab
03
Conditions
Neuroendocrine Neoplasm (NEN)anaplastic thyroid cancer (ATC)adrenocortical carcinoma (ACC)pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT04400474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400474.